A5040739416- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cancer survivorship and care
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Gallbladder and Bile Duct Disorders
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Peptidase Inhibition and Analysis
- Patient-Provider Communication in Healthcare
- Oral and gingival health research
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Complementary and Alternative Medicine Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
Vejle Sygehus
2016-2025
Lillebaelt Hospital
2016-2025
University of Southern Denmark
2016-2025
Region of Southern Denmark
2007-2025
Hôpital Foch
2024
Assistance Publique – Hôpitaux de Paris
2024
Institut Català d'Oncologia
2024
Universitat Autònoma de Barcelona
2024
Hôpital Saint-Antoine
2024
Sorbonne Université
2024
Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 as compared with chemotherapy first-line therapy for MSI-H–dMMR advanced metastatic colorectal cancer is unknown.
Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more 35 three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis even worse, an overall (OS) only 30 Thus, evaluation adjuvant chemotherapy in biliary tract cancer a large randomized trial warranted.
LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard care chemotherapy ± bevacizumab or cetuximab (chemo) as first-line therapy for patients (pts) with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). We present results final PFS analysis. Methods: A total 307 pts MSI-H/dMMR mCRC determined locally ECOG PS 0 1 were randomly...
LBA768 Background: Patients (pts) with MSI-H/dMMR mCRC have poor outcomes standard chemo ± targeted therapies. NIVO IPI are approved in previously treated pts many countries, based on the phase 2 CheckMate 142 study. 8HW (NCT04008030) is a randomized 3 study comparing + or mCRC. We report progression-free survival (PFS) by blinded independent central review (BICR) at prespecified interim analysis for vs 1L setting. Methods: Pts ≥ 18 years recurrent not amenable to surgery and status per...
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
BackgroundPatients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes standard chemotherapy without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H dMMR cancer.MethodsIn this phase 3 open-label trial, we randomly assigned patients unresectable and status according to local testing receive, a 2:2:1 ratio, nivolumab ipilimumab, alone, The dual primary end...
Background. Neoadjuvant chemotherapy has proven valuable in several tumors, but it not been elucidated colon cancer. The present phase II trial addressed the issue high-risk patients selected by computed tomography (CT) scan.Material and methods. Patients with resectable cancer fulfilling following criteria were offered inclusion; Histopathological verification of adenocarcinoma, T3 tumor on CT scan extramural invasion > 5 mm or T4 tumor, age ≥ 18 years, PS ≤ 2, adequate hematology, informed...
3500 Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with MSI-H/dMMR mCRC. The continued to final of overall (OS), planned after 190 OS events or 12 months IA2, whichever occurred first. We present results OS, IA2. Methods: A total 307 pts mCRC and ECOG PS 0 1 were 1:1 pembro 200 mg Q3W for up 2y...
6 Background: KEYNOTE-177 (NCT02563002) evaluated the antitumor activity of pembrolizumab (pembro) vs chemotherapy ± bevacizumab or cetuximab (chemo) as first-line therapy for patients with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). We present results final PFS analysis and PFS2. Methods: Patients locally-determined MSI-H/dMMR mCRC ECOG PS 0 1 were randomized 1:1 to pembro 200 mg Q3W up 2 years investigator’s choice mFOLFOX6...
Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across range solid tumors in trials. We present results from POD1UM-202 (NCT03597295), an open-label, single-arm, multicenter, phase II study evaluating retifanlimab patients with previously treated SCAC.Patients ≥18 years age...
Abstract Background Patients with colorectal metastatic disease have a poor prognosis, limited therapeutic options, and frequent development of resistance. Strategies based on tumor-derived organoids are powerful tool to assess drug sensitivity at an individual level suggest new treatment options or re-challenge. Here, we evaluated the method’s feasibility clinical outcome as applied patients no satisfactory options. Methods In this phase 2, single-center, open-label, non-comparative study...
3503 Background: NIVO + IPI demonstrated superior progression-free survival (PFS) vs chemo in patients (pts) with previously untreated MSI-H/dMMR mCRC the randomized phase 3 CheckMate 8HW study (NCT04008030). We report expanded efficacy analysis from prespecified interim of 1L setting. Methods: Pts unresectable or and status by local testing were enrolled across different lines therapy 2:2:1 to (240 mg) (1 mg/kg) Q3W (4 doses, then 480 mg Q4W), Q2W (6 ± targeted therapies; treatments...
Serous ovarian carcinoma is the most frequent histological subgroup of cancer and leading cause death among gynecologic tumors. The tumor microenvironment cancer-associated fibroblasts (CAFs) have a critical role in origin progression cancer. We comprehensively characterized crosstalk between CAFs cells from malignant fluids to identify specific ligands receptors mediating intercellular communications disrupted pathways related prognosis therapy response.Malignant serous cancer, including...
LBA3503 Background: Locally advanced colon cancer presents a therapeutic challenge regarding improving survival and minimizing side effects by optimizing the timing of surgical systemic treatments. Neoadjuvant chemotherapy is widely accepted approach in numerous cancers as it aims to eliminate micrometastases reduce tumor size. Our study aimed assess impact neoadjuvant on locally compared standard initial surgery. Methods: This was randomized, controlled, phase III clinical trial. Patients...
PURPOSE No biomarker capable of improving selection and monitoring patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance the Immunoscore biopsy (IS B ) was recently suggested in a preliminary study. METHODS This international validation study included 249 clinical complete response (cCR) W&W strategy. Intratumoral CD3+ CD8+ T cells were quantified on pretreatment biopsies digital pathology converted to IS . The primary end...